While Illumina officials said the company's sequencing and microarray product lines experienced "significant growth" in the quarter, they also cautioned that the growth rate for whole-genome BeadChips will soon slow as customers wait for the company to translate content generated by sequencing efforts like the 1000 Genomes Project into new products.